Ocuphire Pharma presents NPDR subset analysis from ZETA-1 Phase 2 trial for APX3330

Opus Genetics, Inc.

Subset analysis: 3% of APX3330 vs 20% of placebo had ≥3-step worsening on binocular DRSS at Week 24.
7% of APX3330 vs 27% of placebo developed PDR (DRSS ≥61) in either eye at Week 24.
APX3330 was well-tolerated; ocular AEs similar between groups, pruritus mild/self-limited.
NPDR subset includes moderate-to-severe NPDR patients without CI-DME at baseline.
Results inform planned trial of APX3330 to slow PDR conversion in high-risk NPDR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.